Journal of the American Academy of Dermatology最新文献

{"title":"Systemic Janus kinase inhibitor treatment for vitiligo: An evidence-based review.","authors":"Siddhartha Sood, Jaymie Varenbut, Ahmed Bagit, Jonah Perlmutter, Khalad Maliyar, Muskaan Sachdeva, Abrahim Abduelmula, Jorge R Georgakopoulos, Asfandyar Mufti, Vimal H Prajapati, Jensen Yeung","doi":"10.1016/j.jaad.2024.08.066","DOIUrl":"10.1016/j.jaad.2024.08.066","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"135-137"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sonographic skin features and shear wave elastography in distinguishing active from inactive morphea lesions: A case-control study.","authors":"Ifa Etesami, Narges Azizi, Reyhaneh Sabrinejad, Sahar Montazeri, Kambiz Kamyab, Maryam Nasimi, Hamidreza Mahmoudi, Faezeh Khorasanizadeh, Ximena Wortsman","doi":"10.1016/j.jaad.2024.09.026","DOIUrl":"10.1016/j.jaad.2024.09.026","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"155-157"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Split thickness skin graft transplantation inspired by paper-cutting: A feasible approach to mitigating surgical misorientation in vitiligo.","authors":"Zhanghui Yue, Maxwell A Kishengere, Xun Zhou, Junhao Li, Yan Wang, Hengguang Zhao, Jianyun Lu, Dan Wang","doi":"10.1016/j.jaad.2024.07.1525","DOIUrl":"10.1016/j.jaad.2024.07.1525","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"e1-e2"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial.","authors":"Kexiang Yan, Fuqiu Li, Xiaodong Bi, Ling Han, Zhenghua Zhang, Rixin Chen, Yuye Li, Litao Zhang, Xiaohua Wang, Linfeng Li, Jianyun Lu, Ai'e Xu, Sen Yang, Yan Lu, Jianfang Sun, Zhiming Li, Xiaohong Zhu, Meiying Jiang, Siping Zhang, Wenqing Wang, Yanling Li, Zudong Meng, Hongyi Li, Kuanhou Mou, Xiuping Han, Shanshan Li, Aijun Chen, Xin Li, Donghua Liu, Chunlei Zhang, Chao Ji, Yu Wang, Hao Cheng, Xiaojing Cui, Xiaoyan Yao, Xiaoyan Bai, Guangchao Dong, Jinhua Xu","doi":"10.1016/j.jaad.2024.09.031","DOIUrl":"10.1016/j.jaad.2024.09.031","url":null,"abstract":"<p><strong>Background: </strong>Vunakizumab, a novel anti-interleukin-17A antibody, has shown promising efficacy for moderate-to-severe plaque psoriasis in a phase 2 trial.</p><p><strong>Objective: </strong>We conducted a double-blind, randomized phase 3 trial (NCT04839016) to further evaluate vunakizumab in this population.</p><p><strong>Methods: </strong>Six hundred ninety subjects were randomized (2:1) to receive vunakizumab 240 mg or placebo at weeks 0, 2, 4, and 8. At week 12, subjects on placebo were switched to vunakizumab 240 mg (weeks 12, 14, 16, and every 4 weeks thereafter). The co-primary endpoints were ≥90% improvement from baseline in the Psoriasis Area and Severity Index score (PASI 90) and a static Physicians Global Assessment score of 0/1 (sPGA 0/1) at week 12.</p><p><strong>Results: </strong>At week 12, the vunakizumab group showed higher PASI 90 (76.8% vs 0.9%) and sPGA 0/1 (71.8% vs 0.4%) response rates, as well as higher PASI 75 (93.6% vs 4.0%), PASI 100 (36.6% vs 0.0%), and sPGA 0 (38.2% vs 0.0%) response rates (all two-sided P < .0001 vs placebo). Efficacy was maintained through week 52 with continuous vunakizumab. Possible treatment-related serious adverse events occurred in 0.9% of vunakizumab-treated subjects.</p><p><strong>Limitations: </strong>Chinese subjects only; no active comparator.</p><p><strong>Conclusion: </strong>Vunakizumab demonstrated robust clinical response at week 12 and through week 52, with good tolerability in moderate-to-severe plaque psoriasis.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"92-99"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.","authors":"Brett G M Hughes, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults, Nikhil I Khushalani, Anne Lynn S Chang, Jean-Jacques Grob, Karl D Lewis, George Ansstas, Fiona Day, Rahul Ladwa, Brian N Stein, Eva Muñoz Couselo, Friedegund Meier, Axel Hauschild, Dirk Schadendorf, Nicole Basset-Seguin, Badri Modi, Sophie Dalac-Rat, Lara A Dunn, Lukas Flatz, Laurent Mortier, Sarah Guégan, Lucie M Heinzerling, Janice M Mehnert, Sabiha Trabelsi, Ainara Soria-Rivas, Alexander J Stratigos, Claas Ulrich, Deborah J Wong, Marie Beylot-Barry, Paolo Bossi, Cristina Bugés Sánchez, Sunandana Chandra, Caroline Robert, Jeffery S Russell, Ann W Silk, Jocelyn Booth, Suk-Young Yoo, Frank Seebach, Israel Lowy, Matthew G Fury, Danny Rischin","doi":"10.1016/j.jaad.2024.06.108","DOIUrl":"10.1016/j.jaad.2024.06.108","url":null,"abstract":"<p><strong>Background: </strong>In the phase 2 EMPOWER-CSCC-1 study (NCT02760498), cemiplimab demonstrated antitumor activity against metastatic cutaneous squamous cell carcinoma (mCSCC) and locally advanced cutaneous squamous cell carcinoma (laCSCC).</p><p><strong>Objectives: </strong>To report final analysis of weight-based cemiplimab in mCSCC and laCSCC (groups 1 and 2), fixed-dose cemiplimab in mCSCC (group 3), and primary analysis of fixed-dose cemiplimab in mCSCC/laCSCC (group 6).</p><p><strong>Methods: </strong>Patients received cemiplimab (3 mg/kg intravenously every 2 weeks [groups 1 and 2]) or cemiplimab (350 mg intravenously [groups 3 and 6]) every 3 weeks. The primary end point was objective response rate (ORR). Duration of response (DOR) and progression-free survival (PFS) are presented per protocol, according to post-hoc sensitivity analyses that only include the period of protocol-mandated imaging assessments.</p><p><strong>Results: </strong>At 42.5 months, ORR for groups 1-3 (n = 193) was 47.2%, estimated 12-month DOR was 88.3%, and median PFS was 26.0 months. At 8.7 months, ORR for group 6 (n = 165 patients) was 44.8%; median DOR and median PFS were not reached. Serious treatment-emergent adverse event rates (grade ≥3) were groups 1-3: 31.1% and group 6: 34.5%.</p><p><strong>Limitations: </strong>Nonrandomized study, nonsurvival primary end point.</p><p><strong>Conclusion: </strong>EMPOWER-CSCC-1 provides the largest prospective data on long-term efficacy and safety for anti-programmed cell death-1 therapy in advanced CSCC.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"68-77"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethics of caring for angry and rude patients.","authors":"Akash Rau, Jane M Grant-Kels","doi":"10.1016/j.jaad.2023.10.059","DOIUrl":"10.1016/j.jaad.2023.10.059","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"205-206"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71482903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Bier anemic spots, cyanosis and urticaria-like eruption syndrome in 42 patients: A peek into dysautonomia.","authors":"Sélia Kearns-Turcotte, Catherine McCuaig, Julie Powell, Maryam Piram, Danielle Marcoux, Afshin Hatami, Jérome Coulombe","doi":"10.1016/j.jaad.2024.08.076","DOIUrl":"10.1016/j.jaad.2024.08.076","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"159-161"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of biorhythmic disorders with melasma: A cross-sectional survey.","authors":"Xuanxuan He, Li Chen, Shanglin Jin, Yuecen Ding, Zhongyi Xu, Leihong Xiang, Chengfeng Zhang","doi":"10.1016/j.jaad.2024.09.050","DOIUrl":"10.1016/j.jaad.2024.09.050","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"185-187"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Fitzpatrick skin type on narrowband UVB therapy outcomes in cutaneous T-cell lymphoma: A retrospective analysis.","authors":"Caroline Chen, Oluwaseyi Adeuyan, Emily R Gordon, Celine M Schreidah, Lauren M Fahmy, Brigit A Lapolla, Thomas Litman, Larisa J Geskin","doi":"10.1016/j.jaad.2024.09.018","DOIUrl":"10.1016/j.jaad.2024.09.018","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"146-148"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How dermatologic surgeons decide to proceed with surgery for nonmelanoma skin cancer when site identification is initially uncertain: A nationwide, multicenter, prospective study.","authors":"Areeba Ahmed, Amanda Maisel-Campbell, Victoria J Shi, Eric Koza, Melissa Ma, Misha Haq, Umer Nadir, Michael D Yi, Loma Dave, Farhana Ikmal Hisham, Katherine A Lin, Sarah A Ibrahim, Bianca Y Kang, McKenzie A Dirr, Juliet L Aylward, Omar Bari, Hamza Bhatti, Diana Bolotin, Basil S Cherpelis, Joel L Cohen, Sean Condon, Sheila Farhang, Bahar Firoz, Algin B Garrett, Roy G Geronemus, Nicholas J Golda, Dyann Helming, Tatyana R Humphreys, Eva A Hurst, Oren H Jacobson, S Brian Jiang, Pritesh S Karia, Arash Kimyai-Asadi, David J Kouba, M Laurin Council, Marilyn Le, Deborah F MacFarlane, Ian A Maher, Stanley J Miller, Eduardo K Moioli, Meghan Morrow, Julia Neckman, Timothy Pearson, Samuel R Peterson, Christine Poblete-Lopez, Chad L Prather, Jennifer S Ranario, Ashley G Rubin, Chrysalyne D Schmults, Andrew M Swanson, Christopher Urban, Y Gloria Xu, Ross Pearlman, Simon Yoo, Vishnu Harikumar, Alexandra Weil, Matthew Schaeffer, Sanjana Iyengar, Emily Poon, Brian A Cahn, Murad Alam","doi":"10.1016/j.jaad.2024.08.073","DOIUrl":"10.1016/j.jaad.2024.08.073","url":null,"abstract":"<p><strong>Background: </strong>Few studies show how dermatologic surgeons manage problems with site identification.</p><p><strong>Objective: </strong>To estimate frequency and characterize management of skin cancer treated by surgery when the anatomic location of the tumor is in question.</p><p><strong>Methods: </strong>Nationwide, prospective, multisite cohort study.</p><p><strong>Results: </strong>Among 17,076 cases at 22 centers, 98 (0.60%) were lesions in question for which site identification was initially uncertain, with these more often in patients who were male, older, and biopsied more than 30 days ago. Surgeons employed on average 5.0 (95% CI: 4.61-5.39) additional techniques to confirm the site location, with common approaches including: re-checking available documentation (90 lesions, 92%); performing an expanded physical examination (89 lesions, 91%); and asking the patient to point using a mirror (61 lesions, 62%). In 15%, photographs were requested from the biopsying provider, and also in 15%, frozen section biopsies were obtained. In 10%, the referring physician was contacted. Eventually, surgeons succeeded in definitively identifying 82% (80 of 98) of initially uncertain sites, with the remaining 18% (18 of 98) postponed. Most postponed surgeries were at non-facial sites.</p><p><strong>Limitations: </strong>Sites were academic centers.</p><p><strong>Conclusions: </strong>When the anatomic location of the tumor is uncertain, dermatologic surgeons use multiple methods to identify the site, and sometimes cases are postponed.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"85-91"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}